Modified vaccinia virus strains for use in diagnostic and therapeutic methods
AssigneeGenelux Corporation
InventorsNanhai Chen, Alexa Frentzen, Aladar A. Szalay, Yong A. Yu, Qian Zhang
Life of this patent
Estimating the term…
Abstract
Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.
Claims34
A recombinant replication competent Lister strain vaccinia virus that encodes a diagnostic or therapeutic protein that comprises an anti-vascular endothelial (VEGF) single chain antibody, and that comprises an inactivated hemagglutinin (HA) gene, thymidine kinase (TK) gene or F14.5L gene.
A recombinant oncolytic vaccinia virus, comprising, an inactivated hemagglutinin (HA) gene, thymidine kinase (TK) gene, and F14.5L gene or locus, wherein the virus encodes a protein comprising an anti-VEGF single chain antibody.
Dependencies are inferred from the claim text.